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Summary
t
In the present study, we describe a novel inhibitory 
receptor, leukocyte-associated immunoglobulin-like 
receptor-1 (LAIR-1), that is constitutively expressed on 
the majority of human peripheral blood mononuclear 
leukocytes. LAIR-1 is a 32 kDa transmembrane glyco­
protein with a single immunoglobulin-like domain and 
a cytoplasmic tail containing two immune receptor 
tyrosine-based inhibitory motifs. LAIR-1 recruits SHP-1 
and SHP-2 phosphatases upon activation, and cross- 
linking of the LAIR-1 antigen on natural killer (NK) cells 
results in strong inhibition of NK cell-mediated cyto­
toxicity. Although it is structurally related to human 
killer cell inhibitory receptors, LAIR-1 does not appear 
to recognize human leukocyte antigen (HLA) class I 
molecules and thus represents a novel HLA class I- 
independent mechanism of NK cell regulation.
Introduction
Natural killer (NK) cells are a subpopulation of lympho­
cytes distinct from T and B cells. NK cells are capable 
of lysing transformed and virus-infected cells without 
apparent presensitization, and are considered important 
cellular components of innate immunity (reviewed by 
Trinchieri, 1989). The molecular interactions that trigger 
the cytolytic functions of NK cells are not completely 
understood. Monoclonal antibodies (MAbs) recognizing 
adhesion and signaling molecules, however, have been 
shown to induce NK cell-mediated cytotoxicity in vitro 
(Siliciano et a l. /1985; Lanier et al., 1988b; Moretta et 
al., 1991; Shibuya et al., 1996).
In recent years, progress has been made in under­
standing the receptors responsible for inhibiting NK cell 
functions. The early observation that NK cells selectively 
kill targets that lack major histocompatibility complex 
(MHC) on their surface (Karre et al., 1986), eventually
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led to the identification of inhibitory receptors present 
on NK cells that bind MHC expressed on the target cell. 
In humans, two separate families of inhibitory receptors 
have been identified on NK cells: killer cell inhibitory 
receptors (KIRs), which are immunoglobulin superfamily 
members (Colonna and Samaridis, 1995; D’Andrea et 
al., 1995; Wagtmann et al., 1995; Lanier and Phillips, 
1996), and the CD94/NKG2 receptors of the C-type lec­
tin superfamily (Lazetic et al., 1996; Phillips et al., 1996; 
Sivori et al., 1996). All of these inhibitory receptors pos­
sess cytoplasmic tails with immune receptor tyrosine- 
based inhibitory motifs (ITIMs) (Thomas, 1995). Upon 
phosphorylation, cytoplasmic ITIMs bind the SH2 do­
mains of certain phosphatases, leading to down-regula- 
tion of cell activation (Scharenberg and Kinet, 1996).
To identify molecules important in the regulation of 
NK cell cytotoxicity, we immunized mice with human 
NK cells and screened for MAbs that were capable of 
inhibiting NK cell mediated cytotoxicity. A MAb, desig­
nated DX26, that when cross-linked delivered a negative 
signal to NK cells, was identified. The antigen recog­
nized by DX26 MAb (designated leukocyte- associated 
immunoglobulin-like receptor-1 [LAIR-1]) is a member 
of the immunoglobulin superfamily, with homology to 
KIRs, and possesses two ITIMs in its cytoplasmic do­
main. LAIR-1, however, does not appear to recognize 
class I human leukocyte antigens (HLA) and thus repre­
sents a novel (HLA-independent) inhibitory molecule 
that may play an important role in the regulation of NK 
cell function.
Results
DX26 Identifies an Inhibitory Receptor 
on NK Cells
To identify molecules that are involved in negative sig­
naling, mice were immunized with a human NK cell clone 
and antibodies were screened for their capacity to inhibit 
NK cell-mediated lysis of Fc-receptor (FcR)-bearing tar­
gets. A MAb, designated DX26, was isolated that effi­
ciently inhibited the NK cell-mediated cytotoxicity of 
the human Fc /^Rll (CD32) transfected Epstein-Barr virus 
(EBV)-transformed B cell line, 721.221/CD32 (Figure 1). 
Cytolysis of the FcR-negative parent line, 721.221, how­
ever, was not affected by DX26 MAb, indicating that 
FcR cross-linking of LAIR-1 (the antigen recognized by 
DX26 MAb) was required to deliver the negative signal 
(Figure 1). Further evidence for the inhibitory signal- 
transducing capabilities of LAIR-1 was obtained using 
the FcR-expressing mouse mastocytoma cell line, P815. 
Many NK cell clones lyse P815 in the presence of MAbs 
against positive signal molecules, such as CD2, CD16, 
CD69, and DNAM-1 (Lanier et al., 1997). Antibody-medi­
ated NK cell lysis of P815 was also inhibited by DX26 
MAb, indicating that cross-linking of LAIR-1 led to inhibi­
tion of cytotoxicity, even in the presénce of strong posi­
tive signals (Figure 2).
Since the majority of resting NK cells express LAIR-1, 
experiments were undertaken to determine whether
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Figure 1. DX26 MAb Inhibits NK Cell Cytotoxicity When Cross- 
Linked by FcR on the Target Cell
NK clone KS279.p1 was assayed for lysis of 721.221 target cells or 
721.221 transfectants expressing the human FC7 RII (721/CD32) in 
the presence of DX26 MAb or control lgG1. DX26 MAb and control 
lgG1 were used at 10 jj-g/’ml. Data are representative of experiments 
performed with several NK cell clones.
LAIR-1 functions as an inhibitory receptor on freshly 
isolated NK cells. Resting NK cells were purified from 
peripheral blood to greater than 90% purity and assayed 
for cytolysis of anti-CD16 MAb-coated P815 in the pres­
ence or absence of DX26 MAb. As was observed with 
NK cell clones, freshly isolated NK cell cytolysis of 
anti-CD16 coated P815 was significantly inhibited by 
the presence of DX26 MAb (Figure 3A). Cytolysis of the 
NK-sensitive tumor cell line K562 by NK cells in freshly 
isolated peripheral blood mononuclear cells (PBMCs) 
was also inhibited by DX26 MAb (Figure 3B). DX26 
F(ab)'2 fragments did not affect killing of K562, which 
further substantiates the necessity for LAIR-1 to be 
cross-iinked in order to generate a negative signal in 
NK cells. Likewise, NK cell cytotoxicity against a panel 
of FcR-negative tumor cells was unaffected by the pres­
ence of the DX26 MAb (data not shown).
LAIR-1 Is a Broadly Expressed Leukocyte Antigen 
Phenotypic analysis of human peripheral blood lympho­
cytes demonstrated that LAIR-1 is a widely expressed 
molecule on peripheral blood leukocytes. LAIR-1 is 
prominently expressed on norma! peripheral blood 
CD3+CD4+ 1 cells (70%-80%), CD3+CD8+ Tcells (80%- 
90%), CD3 “CD56+ NK celts (95%-100%), CD3CD19+
B cells (80%—90%), and CD3"CD14+ monocytes (99%- 
100%) (Figures 4A-4C). LAIR-1, however, was not ex­
pressed on peripheral blood granulocytes, platelets, or 
red blood cells (data not shown). The majority of human 
fetal thymocytes, also expressed LAIR-1 (Figure 4D), as 
well as all NK cell and T cell clones and all T cell tumor 
cell lines (Table 1). The long-term cultured NK lines, 
NKL and NK92, were negative for LAIR-1 , as were EBV- 
transformed B cell lines, the B cell tumor Daudi, the NK- 
like tumor cell line YT, and several nonhematopoietic 
cell lines (Table 1).
cDNA Cloning of LAIR-1
To identify a LAIR-1-encoding cDNA, 293T cells were 
transfected with a cDNA library prepared from a poly­
clonal human NK cell line (Lanier et al., 1994), and ex­
pression cloning using flow cytometry was performed. 
As shown in Figure 5A, a single cDNA that encoded a 
protein recognized by the DX26 MAb was obtained. The 
LAIR-1 cDNA was 1728 bp, containing an 864 bp open 
reading frame encoding a type I membrane protein with 
a 21 amino acid (aa) leader sequence, a 142 aa extracel­
lular domain, a 23 aa transmembrane domain, and a 101 
aa cytoplasmic region (Figures 5B and 5C). One pair of 
cysteines in the extracellular domain generates a single 
immunoglobulin-like domain, thus classifying LAIR-1 as 
a member of the immunoglobulin superfamily. The extra­
cellular domain had one potential N-linked glycosylation 
site. The predicted molecular weight of the LAIR-1 poly­
peptide is 32 kDa. The cytoplasmic domain contained 
the amino acid sequences VTYAQL and ITYAAV, spaced 
by 24 aa, which fit the consensus sequences for ITIMs 
(V/lxYxxxL/V) (D’Ambrosio et al., 1995). Using fluorescence 
in situ hybridization, the LAIR-1 gene was mapped to chro­
mosome 19q13.4.
Northern blot analysis of PBMCs showed two pre­
dominant transcripts of approximately 1.7 and 3 kb 
(Figure 6). Transcripts were found in human monocytes, 
Jurkat, U937, and human NK cell clones, but not in LAIR- 
negative cell lines, such as the EBV-transformed B cell 
line JY (Figure 6). Southern blot analysis of human geno­
mic DNA demonstrated a relatively simple hybridization 
pattern for LAIR-1 (data not shown). This uncomplicated
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Figure 2. DX26 MAb Inhibits NK Cell Cyto­
toxicity in the Presence of Cross-Linking MAb 
to Positive Signaling Structures
NK clone KS279.p1 was assayed for lysis of 
P815 target cells, when stimulated with 5 jjig/ 
ml MAb against CD16 (A), CD2 (B), CD69 (C), 
or DNAM-1 (D) in the presence of DX26 MAb 
or control lgG1. DX26 MAb and control IgGI 
were used at 1 0 fjig/ml. Data are representa­
tive of experiments performed with several 
NK cell clones.
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Figure 3. DX26 MAb Inhibits Cytolytic Function of Resting NK Cells
(A) NK cells were purified from human peripheral blood and assayed 
for lys/s of P81S cells when stimulated with 5 \ig/ml anti-CD16 in 
the presence of 10 fig/ml control lgG1 or DX26 MAb. Data are 
representative of three independent experiments with cells from 
different donors.
(B) Freshly isolated PBMCs were used as effector cells and assayed 
for spontaneous killing of K562 cells in the presence of 10 \lq/  
ml control lgG1 , DX26 MAb, or DX26 F(ab) '2 fragments. Data are 
representative of experiments with cells from four different donors.
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genomic organization suggests that the LAIR-1 probe 
hybridizes with a single or relatively few genes.
Biochemistry of LAIR-1
To study the biochemical features of LAIR-1} the protein 
was immunoprecipitated with DX26 MAb from 125l- 
labeled lysates of 293T cells transfected with the LAIR-1 
cDNA and two peripheral blood human NK cell clones. 
LAIR-1 precipitated from LAIR-1-transfected cells was 
a ^40 kDa monomer when analyzed by SDS-poly- 
acrylamide gel electrophoresis (SDS-PAGE) under both 
nonreducing and reducing conditions (Figure 7). The 
mobility of LAIR-1 decreased from ~40 to ~32 kDa after 
treatment with N-glycosidase F, in agreement with the 
predicted protein size and one N-linked glycosylation 
site (Figure 7). Immunoprécipitation with DX26 MAb from 
lysates of two human NK cell clones revealed, in addition 
to LAIR-1 at 40 kDa, a smaller protein migrating at ~32 
kDa (Figure 7). This smaller protein also decreased in 
size after deglycosylation. Whether this represents a 
distinct LAIR-1 isoform or a proteolytic cleavage product 
of LAIR-1 is unknown.
LAIR-1 Binds SHP-1 and SHP-2
The existence of two consensus sequences for ITIMs 
within the cytoplasmic domain of LAIR-1 suggested that 
the generation of an inhibitory signal in NK cells was 
manifested by the recruitment of SH2-containing tyro­
sine phosphatases-1 and/or -2 (SHP-1 and/or SHP-2). 
To determine whether LAIR-1 was capable of binding 
protein tyrosine phosphatases, a NK cell clone was stim­
ulated with pervanadate (an inhibitor of protein tyrosine 
phosphatases that induces tyrosine phosphorylation
Figure 4. LAIR-1 Expression on Peripheral Blood Leukocytes and 
Fetal Thymocytes
(A-C) PBMCs were stained with DX26 MAb and visualized by phy- 
coerythrin (PE)-conjugated goat-anti mouse-IgG; CyChrome-conju- 
gated CD3 MAb; and fluorescein isothiocyanate (FITC)-conjugated 
CD4, CD8 , CD56, CD19, or CD14 MAb. Cells were analyzed on a  
FACScan and gated for CD3+ lymphocytes (A), CD3~ lymphocytes
(B), or monocytes (C) on the basis of forward and side scatter profiles 
and anti-CD3 MAb staining,
(D) Human fetal thymocytes were stained with DX26 MAb visualized 
by PE-conjugated goat anti-mouse IgG and CyChrome-cònjugated 
anti-CD3 MAb.
Markers were set using appropriate isotype control antibodies. Data 
are representative of three independent experiments.
(O’Shea et al., 1992), lysed, and immunoprecipitated 
with DX26 MAb. Immunoprecipitates were then ana­
lyzed by Western blot using antibodies specific for 
SHP-1 and SHP-2. As shown in Figure 8, both SHP-1 and 
SHP-2 associated with tyrosine-phosphorylated LAIR-1. 
These results suggest that recruitment of SHP-1 and 
SHP-2 may be involved in mediating the negative signal 
transduced via engagement of the LAIR-1 molecule.
a
Discussion
Regulation of immune responses is determined by the 
balance of positive signals to initiate an immune re­
sponse and inhibitory mechanisms to prevent excessive 
inflammatory responses and autoimmunity. Here we 
describe a novel inhibitory receptor, LAIR-1, that may 
function to down-regulate immune responses. LAIR-1 
is a novel member of the immunoglobulin superfamily 
that is expressed on the majority of peripheral blood
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mononuclear leukocytes. Cross-linking of LAIR-1 on hu­
man NK cells delivers a potent inhibitory signal that is 
capable of inhibiting target cell lysis by both resting and 
activated NK cells in vitro.
LAIR-1 is structurally related to several other inhibitory 
immunoglobulin superfamily members, including human 
KIRs (Colonna and Samaridis, 1995; D’Andrea et al., 
1995; Wagtmann etal,, 1995), human FcRa (Maliszewski 
et al., 1990), bovine FC7RII (Zhang et al., 1995), mouse 
gp49 (Arm et al., 1991 ; Rojo et al., 1996), and mouse 
gp91 or paired immunoglobulin-like receptors (Hayamì 
et al., 1997; Kubagawa et al., 1997). The overall homol­
ogy of LAIR-1 with these proteins is less than 30%. 
LAIR-1, however, shows slightly higher homology (32%) 
to members of a recently identified novel group of genes 
designated immunoglobulin-like transcripts (ILTs) (Celia 
et al., 1997; Samaridis and Colonna, 1997). LAIR-1, KIRs, 
ILTs, and FcRa all are localized to the same human 
chromosome region, 19q13.4, suggesting that these 
molecules evolved from a common ancestral gene.
Consistent with the inhibitory signal given to NK cells, 
the cytoplasmic domain of LAIR-1 contains two tyro­
sine-based inhibitory motifs (VTYAQL and ITYAAV), In 
the human KIRs, similar ITIMs were found to recruit 
phosphatases (primarily SHP-1) upon tyrosine phos­
phorylation and thereby to inhibit positive signal trans­
duction via other receptors (Burshtyn et al., 1996; Camp­
bell et al., 1996; Fry et al., 1996; Olcese et al., 1996; 
Scharenberg and Kinet, 1996). Indeed, activation of NK 
cells with sodium pervanadate resulted in the binding 
of both SHP-1 and SHP-2 phosphatases to LAIR-1 . This 
suggests that the binding of these phosphatases to 
LAIR-1 might lead to inhibition of downstream molecular 
events associated with cellular activation.
LAIR-1 may be a member of a novel family of highly 
related receptors, similar to the situation with ILTs, gp49, 
and KIRs. Northern blot analysis revealed at least two 
distinctive mRNA transcripts, and immunoprecipita-
LAIR-PE
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Figure 5. cDNA Cloning of LAIR-1
tions with DX26 MAb identified two proteins with slightly 
different molecular weights after deglycosylation. We 
have recently identified, by colony hybridization of a T 
cell-derived cDNA library, a putative family member of 
LAIR-1, which we have designated LAIR-2 (EMBL/Gen- 
Bank/DDBJ accession number AF013250). LAIR-2 con­
tains one immunoglobulln-like domain, which is 84% 
homologous to LAIR-1; however, it lacks both a trans­
membrane and a cytoplasmic domain, suggesting that 
LAIR-2 is a secreted protein (data not shown). Further 
studies are required to delineate the functions of LAIR-2 
as well as to define other possible LAIR-1 family members.
We have not yet defined the ligand(s) for LAIR-1. Since
Table 1. Expression of LAIR on Human Tumor Ceil Lines
Cell Line Type
Mean Fluorescence Intensity 
Control lgG1 DX26 MAb
HUT78» T cell tumor <5 25.8
Peer T cell tumor <5 29.1
Molt4 T cell tumor <5 30.7
CEM T cell tumor <5 92.7
Jurkat T cell tumor <5 47.1
HL60 Promyeloid tumor <5 46.9
U937 Myeloid tumor <5 49.5
*
721.221 EBV B cell <5
V
<5
JY EBV B cell <5 <5
Daudi B cell tumor <5 <5
YT NK ceil tumor <5 <5
NKL NK celi line <5 <5
NK92 NK cell line <5 <5
Colo205 Colon carcinoma <5 <5
293T Embryonic kidney <5 <5
FA-1 Teratocarcinoma <5 <5
FO-1 Melanoma <5 <5
Cells were stained with control ÌgG1 or DX26 MAb and PE-conjugated goat-anti-mouse-IgG as a second step. Cells were analyzed on a 
FACScan. Data are representative of three Independent experiments.
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(A) LAIR-1 expression on 293T cells trans­
fected with the pJFE14 vector containing an 
irrelevant insert or LAIR-1 cDNA.
(B) Nucleotide and predicted amino acid se­
quences of LAIR-1. The leader sequence and 
putative transmembrane domain are under­
lined. The potential N-linked glycosylation 
site in the extracellular domain is circled. The 
ITIM sequences in the cytoplasmic domain 
are indicated by underlining and bold print. 
These sequence data are available from 
EMBL/GenBank/DDBJ under accession num­
ber AF013249.
(C) Schematic diagram of the LAIR-1 protein. 
The diagram indicates leader peptide, extra­
cellular, transmembrane, and cytoplasmic re­
gions and the pair of cysteine residues in the 
extracellular domain potentially able to par­
ticipate in intrachain disulfide bonding for the 
formation of an immunogloblulin-like domain.
C TGGCC TC TGCACCTGAGGGTAG AAAGTCACTCTAGGAAAAGCC TGAAGCAGC CATTTG 1003
GAAGGCTTCCTGTTGGATTCCTCTTCATCTAGAAAGCCAGCCAGGCAGCTGTCGTGGAG 1 0 6 2
ACAAGAGCTGGAGACTGGAGGTTTCTAACCAGCATCCAGAAGGTTCGTTAGCCAGGTGG 1 1 2 1
TCCCTTCTACAATCGAGCAGCTCCTTGGACAGACTGTTTCTCAGTTATTTCCAGAGACC 1 1 8 0
CAGCTACAGTTCCCTGGCTGTTTCTAGAGACCCAGCTTTATTCACCTGACTGTTTCCAG 123  9
AGACCCAGCTAAAGTCACCTGCCTGTTCTAAAGGCCCAGCTACAGCCAATCAGCCGATT 1 2 9 8
TCCTGAGCAGTGATGCCACCTCCAAGCTTGTCCTAGGTGTCTGCTGTGAACCTCCAGTG 1 3 5 7
ACCCCAGAGACTTTGCTGTAATTATCTGCCCTGCTGACCCTAAAGACCTTCCTAGAAGT 1 4 1 6
CAAGAGCTAGCCTTGAGACTGTGCTATACACACACAGCTGAGAGCCAAGCCCAGTTCTC 1 4 7 5
TGGGTTGTGCTTTACTCCACGCATCAATAAATAATTTTGAAGGCCTCACATCTGGCAGC 1534
CCCAGGCCTGÇTCCTGGGTGCATAGGTCTCTCGGACCCACTCTCTGCCTTCACAGTTGT 1593
TCAAAGCTGAGTGAGGGAAACAGGACTTACGAAAACGTGTCAGCGTTTTCTTTTTAAAA 1652
TTTAAT TG ATC AGGATTGTAC GTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1 7 1 1  
AAAAAAAAAAAAAAAGG
the DX26 MAb does not interfere with HLA class I recog­
nition by a large panel of NK clones (data not shown), 
it seems unlikely that LAIR-1 recognizes HLA class I 
molecules. Furthermore, since LAIR-1 is broadly ex­
pressed on the majority of mononuclear leukocytes, its 
ligand(s) may demonstrate a more restricted expression. 
Experiments are presently underway using LAIR-1 fu­
sion proteins to probe various tissues and cell types for 
potential ligands for this inhibitory receptor.
At present, we have studied the function of LAIR-1 
only on peripheral blood NK cells. DX26 MAb also stains 
peripheral blood B cells, T cells, and monocytes as well 
as the majority of thymocytes. The functional signifi­
cance of the molecules recognized by DX26 MAb on 
these other mononuclear leukocytes remains to be de­
termined. However, it is reasonable to predict that
LAIR-1, or closely related family members, will be found 
to provide a mechanism of regulation in a variety of 
immune interactions.
Experimental Procedures 
Cells
Peripheral blood from healthy donors was purchased from Stanford 
Blood Center (Stanford, CA). PBMCs were isolated by Ficoll- 
Hypaque centrifugation. Resting NK cells were purified from PBMCs 
by magnetic bead depletion as described (Phillips et al., 1992).
NK clones were established as described (Phillips et al., 1991) 
and maintained in culture using the method of Yssel et al. (1984).
The HLA class I—deficient EBV-transfomned lymphoblastoid cell 
line 721.221 has been described (Shimizu and DeMars, 1989). DT287 
is a stable transfectant of 721.221, expressing human FC7 RII (CD32), 
generated in our laboratory. 293 cells expressing SV40 large T anti­
gen (293T) were generously provided by T. Kitamura (DNAX). P815,
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Figuro 6 . Expression of LAIR-1 mRNA
Total RNA of human monocytes {lane 1), Jurkat (lane 2), U937 (lane 
3), JY (lane 4), and two different human NK cel! clones (lanes 5 and 
6 ) was analyzed for LAIR transcripts using a ^P-iabeled LAIR-1 
probe (top). As a control for the amount of RNA in each lane, hybrid­
ization with a ß-actin probe of the same blot is also shown (bottom).
HUT78, Peer, Molt4, CEM, Jurkat, HL60, U937, JY, Daudi, Colo205, 
PA-1, and K562 were obtained from the American Type Culture 
Collection (Rockville, MD). YT-2C2 Is a NK-like tumor cell line that 
was kindly provided by K. Smith (Yodoi et al., 1985). FO-1 is a human 
melanoma cell line that was a kind gift of S. Ferrone (D'Urso et al., 
1991). NKL Is an NK cell line generously provided by M. Robertson 
{Dana-Farber, Boston, MA) (Robertson et al., 1996). The NK92 cell 
line was obtained from H. G. Klingemann (Gong et al., 1994).
Antibodies
The DX26 (immunoglobulin G1 [lgG1])- producing hybridoma was 
generated by fusing the Sp2/0 myeloma ceil line with splenocytes 
from a BALB/c mouse immunized with a human NK clone. Antibod­
ies against DNAM-1 (DX11) (Shibuya et al„ 1996) and CD69 (L78) 
(Testi et al., 1989) have been described. DX10 (mouse lgG1 ) is a 
CD2 MAb that was generated in our laboratory. AH other MAbs 
were generously provided by Becton Dickinson Immunocytometry 
Systems (San Jose, CA).
Cytotoxicity Assay
Cell lines were labeled with51 Cr and used as targets in a 4 hr radioiso­
tope release assay as described (Lanier et alM 1983), Data are ex­
pressed as the mean of triplicate cultures. Spontaneous radioiso­
tope release did not exceed 1 0 % of maximum release as determined 
by lysis of target cells with 10% Triton-X 100, The percentage spe­
cific lysis was calculated as (cpm specific 51Cr release -  cpm spon­
taneous 51Cr release)/(cpm maximum 51Cr release -  cpm spontane­
ous 51 Cr release) x 1 00.
Expression Cloning
A cDNA library was constructed from an interleu kin-2-dependent 
polyclonal NK line, as described (Lanier et al., 1994). cDNA cloning 
by transient expression in 293T cells was performed as described 
(Aruffo and Seed, 1987), with modifications (Lanier et a!., 1994).
RNA and DNA Analysis
cDNA was sequenced by using the dideoxy termination technique 
with a Sequenase 2 .0  kit (United States Biochemical, Cleveland, 
OH) and by using an automated nucleic acid sequencer (Applied 
Biosytems, Foster City, CA).
The 1.7 kb LAIR-1 cDNA was released from the plasmid by diges­
tion with Noti I and Bstxll restriction enzymes, labeled using random 
hoxamer primers (Feinberg and Vogelstein, 1983), and used as a
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Figure 7. LAIR-1 Is a 32 kDa Protein Expressed as a Monomer
125l-labeled labeled 293T ceils, transfected with the LAIR-1 encoding  
cDNA (lane 3 and 4) and two different human NK cell clones (lanes  
1, 2, 5, and 6 ) were lysed, and LAIR-1 antigen was immunoprecipi­
tated with DX26 MAb. The immunoprecipitates were treated w ith  
N-glycosidase where indicated and analyzed by SDS-PAGE u n d er  
nonreducing conditions. Analysis under reducing conditions re ­
sulted in an identical migration of the proteins (data not shown).
probe in Northern and Southern blot analyses. Total RNA was is o ­
lated with RNA-STAT-6 Q (Teltest ‘B’, Friendswood, TX). RNA and  
DNA were separated by electrophoresis in agarose gels, transferred 
to membranes, and hybridized with the 32P-labeled probes at 65°C  
in Quickhyb (Stratagene Cloning Systems, La Jolla, CA) according 
to the instructions of the manufacturer. Radioactivity was measured 
using a phosphoimager (Molecular Dynamics, Sunnyvale, CA).
The chromosomal localization of \he LAIR-1 gene was determined 
using a biotinylated LAIR-1 probe for in situ hybridization to m e ta ­
phases from two normal males as described (Callen et al., 1990)»
Biochemistry
To characterize biochemically the antigens recognized by D X 26  
MAb, cells were labeled with 1251 and antigens immunoprecipitated
aLAIR clgG lysate
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Figure 8 . SHP-1 and SHP-2 Are Associated with LAIR-1 in NK C ells  
upon Pervanadate Stimulation
A human NK cell clone was incubated in the absence or presence 
of pervanadate for 1 0  min at 37°C. Cells were lysed and LAIR - 1  
proteins were immunoprecipitated with DX26 MAb. As a control, 
immune precipitation with control IgG is shown. Immunoprecipitates 
were separated by SDS-PAGE and blotted with SHP-1 (top) a n d  
SHP-2 (bottom) antibodies. As a control for the presence of SHP - 1  
and SHP-2 , whole cell lysates were run on the same gel (right lanes).
LAIR-1, a Novel Inhibitory Receptor
289
by a procedure described previously (Lanier et aL, 1988a). Immuno­
precipitates were separated by SDS-PAGE and visualized by expo­
sure to a phosphoimager screen.
To demonstrate association of phosphatases with phosphory- 
lated LAIR-1, NK cells were stimulated with 100 mM sodium pervan­
adate for 10 min at 37°C (O’Shea et al., 1992). Cells were lysed in 
1 % NP40 in the presence of phosphatase inhibitors as described 
(Phillips et al., 1996). LAIR-1 protein was immunoprecipitated by 
DX26 MAb and protein G-sepharose (Pharmacia, Alameda, CA). 
Immunoprecipitates were separated by SDS-PAGE and transferred 
to Immobilon-P membranes (Millipore, Bedford, MA). The mem­
branes were blocked and incubated with polyclonal rabbit antibod­
ies against SHP-1 and SHP- 2  (C18 and C19, Santa Cruz Labora­
tories), followed by horseradish peroxidase conjugated anti-rabbit 
immunoglobulin (Amersham, Arlington Heights, IL). Proteins were 
detected by enhanced chemiluminescence (Supersignal Substrate, 
Pierce, IL).
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